Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review
- PMID: 38003785
- PMCID: PMC10675296
- DOI: 10.3390/pathogens12111320
Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review
Abstract
Host genetic factors significantly influence susceptibility to SARS-CoV-2 infection and COVID-19 severity. Among these genetic factors are single-nucleotide variants (SNVs). IFNAR2 and IFNAR1 genes have been associated with severe COVID-19 in populations from the United Kingdom, Africa, and Latin America. IFNAR1 and IFNAR2 are subunits forming the type I interferon receptor (IFNAR). SNVs in the IFNAR genes impact protein function, affecting antiviral response and disease phenotypes. This systematic review aimed to describe IFNAR1 and IFNAR2 variants associated with COVID-19 susceptibility and severity. Accordingly, the current review focused on IFNAR1 and IFNAR2 studies published between January 2021 and February 2023, utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The electronic search was conducted in PubMed databases using Boolean operators and inclusion and exclusion criteria. Of the 170 literature pieces, 11 studies were included. We include case reports of rare SNVs, defined by minor allele frequency (MAF) < 1%, and genome-wide associated studies (GWAS). Variants in IFNAR1 and IFNAR2 could potentially be new targets for therapies that limit the infection and the resulting inflammation by SARS-CoV-2 infection.
Keywords: COVID-19; IFNAR1; IFNAR2; antiviral response; single-nucleotide variants.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
IFNAR2 Is Required for Anti-influenza Immunity and Alters Susceptibility to Post-influenza Bacterial Superinfections.Front Immunol. 2018 Nov 9;9:2589. doi: 10.3389/fimmu.2018.02589. eCollection 2018. Front Immunol. 2018. PMID: 30473701 Free PMC article.
-
Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility.J Glob Antimicrob Resist. 2021 Sep;26:239-240. doi: 10.1016/j.jgar.2021.06.005. Epub 2021 Jul 15. J Glob Antimicrob Resist. 2021. PMID: 34273592 Free PMC article.
-
Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.Allergy Asthma Clin Immunol. 2023 Aug 9;19(1):69. doi: 10.1186/s13223-023-00831-1. Allergy Asthma Clin Immunol. 2023. PMID: 37559153 Free PMC article.
-
SARS-CoV-2 Variants and Clinical Outcomes: A Systematic Review.Life (Basel). 2022 Jan 25;12(2):170. doi: 10.3390/life12020170. Life (Basel). 2022. PMID: 35207458 Free PMC article. Review.
-
Genome-wide association studies of COVID-19: Connecting the dots.Infect Genet Evol. 2022 Dec;106:105379. doi: 10.1016/j.meegid.2022.105379. Epub 2022 Oct 21. Infect Genet Evol. 2022. PMID: 36280088 Free PMC article. Review.
Cited by
-
Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.Front Immunol. 2024 Sep 16;15:1462628. doi: 10.3389/fimmu.2024.1462628. eCollection 2024. Front Immunol. 2024. PMID: 39351231 Free PMC article. No abstract available.
-
Potential associations of selected polymorphic genetic variants with COVID-19 disease susceptibility and severity.PLoS One. 2025 Jan 3;20(1):e0316396. doi: 10.1371/journal.pone.0316396. eCollection 2025. PLoS One. 2025. PMID: 39752416 Free PMC article.
-
Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.J Pers Med. 2025 Apr 17;15(4):156. doi: 10.3390/jpm15040156. J Pers Med. 2025. PMID: 40278335 Free PMC article.
References
-
- Órpez-Zafra T., Pavía J., Hurtado-Guerrero I., Pinto-Medel M.J., Bada J.L.R., Urbaneja P., Suardíaz M., Villar L.M., Comabella M., Montalban X., et al. Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. Mult. Scler. J. 2017;23:937–945. doi: 10.1177/1352458516667564. - DOI - PubMed
-
- Murphy K., Travers P., Walport M. Janeway’s Immunobiology. Garland Science; New York, NY, USA: 2008.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous